(CWB:   Crausaz Wordsworth Building)

Wednesday 18 September

10.00 - 11.25   Delegates Arrive, Registration/Tea & Coffee/put up posters (CWB – Foyer & Plenary)
11.30 - 11.45   DMDG Chair opening address: Becky Scott, GSK (Auditorium)
11.45 - 12:45   Keynote Speaker: Auditorium
Creating the future of drug development (and use)
Dr Richard Peck, Global Head, Clinical Pharmacology, F Hoffmann la Roche Ltd
12.50 - 13.45   Lunch, Posters and Exhibition (CWB – Foyer & Plenary)
13.50 - 15.20   Session 1: Biologics biotransformation: The new frontier in metabolite ID (Auditorium)
Chair: Kevin Brady, UCB
  1. Metabolite Identification for Peptides and Larger Biologics: an Innovative Semi-Quantitative Mixed Approach
    Marcella Petrone, AstraZeneca and Nick White, AstraZeneca
  2. In vitro strategy to evaluate therapeutic protein biotransformation during pre-clinical development: Opportunities and remaining challenges
    Simon Hauri, Roche
  3. Biologic Biotransformation Studies in Action at GSK
    Scott Summerfield, GSK
15.25 - 16:00   Tea/Coffee & room key collection (CWB – Foyer & Plenary)
16.05 - 17.35   Session 2: The forgotten organ – The gut microbiome (Auditorium)
Chair: Ian Wilson, Imperial College
  1. What did the gut microbiota ever do for us?
    Ian Wilson, Imperial College
  2. The influence of the microbiome on pharmacokinetics – fact or myth?
    Edna Choo, Genentech Inc
  3. Gut microbiota biotransformation of some AstraZeneca oncology drugs and metabolites
    Graeme Scarfe, AstraZeneca
17.45 - 18.45   Session 3: Student Poster Blitz (Auditorium)
Chairs: Claire Henson, Pharmaron UK & Lilly Collins, Sygnature Discovery
19.00 - 20.30   Dinner (Dining Hall)
20.00 - 22.00   Poster Session, Exhibition, Drinks Reception (CWB – Foyer & Plenary)
Thursday 19 September

08.30 - 10.00   Session 4: PEGylated proteins (Auditorium)
Chair: Jesper Kammersgaard Christensen, NovoNordisk
  1. Current view on the safety of PEGylated biologics
    Andreas Baumann, Bayer
  2. Rat PEG distribution data and how it was used in relation to human clinical safety of a PEGylated protein
    Ola Sternebring, NovoNordisk
  3. Quantitation of total PEG in biological matrices by NMR
    Davindera Sanghera, Intertek
10.05 - 10.35   Tea/Coffee, Posters and Exhibition (CWB – Foyer & Plenary)
10.40 - 12.10   Session 5: AI in DMPK (Auditorium)
Chair: John Overington, Medicines Discovery Catapult
  1. Title TBC
    Andreas Bender, University of Cambridge
  2. Title TBC
    Nigel Green, AstraZeneca
  3. Combining Quantum Mechanics and Machine Learning to Predict Drug Metabolism
    Matt Segal, Optibrium Ltd
12.15 - 13.15   Lunch, Posters and Exhibition (CWB – Foyer & Plenary)
12.40 - 13.10   DMDG ABM (CWB – Syndicate)
13.20 - 14.50   Session 6: Drug discovery in the ‘Beyond rule of 5’ space (Auditorium)
Chair: Matthias Wittwer, Roche
  1. The Targeted Protein Degrader Gold Rush: "It’s ADME Jim, but not as we know it"
    Caroline Rynn, Roche
  2. Novel approach towards protein binding measurement of challenging bRo5 compounds
    Abhishek Srivastra, AstraZeneca
  3. Modelling cell permeability beyond the Rule-of-5
    Pär Matsson, Sahlgrenska Academy, University of Gothenburg
14.55 - 15.25   Tea/Coffee, Posters and Exhibition (CWB – Foyer & Plenary)
15.30 - 17.00   Session 7: Free communications (Auditorium)
Chair: Andrew McEwen, Reviresco Solutions
  1. Evaluating the role of solubility in oral absorption using physiologically based pharmacokinetic (PBPK) modeling
    Sheila-Annie Peters, Merck
  2. What every DMPK scientist should know about paracetamol metabolism in the pig
    Ian Wilson, Imperial College
  3. Quantitative Prediction of Drug-Drug Interactions with Common Statin Co-meds: A framework for decision-making within Drug Discovery/Development
    Hayley Atkinson, Cyprotex
17.10 - 18.40   Session 8: Debate: Bioimaging – which modality is best? (Auditorium)
Chair: Steve Hood, GSK
  1. For Mass Spec Imaging
    Andy West, GSK
  2. For Optical Imaging
    Pete Watson, Cardiff University
  3. For Radioactive Imaging
    Claire Henson, Pharmaron UK
19.30 - 20.00   Drinks Reception (Bar)
20.00 - late   Conference Dinner (Dining Hall) & Entertainment (Bar)
Friday 20 September

08.50 - 10.20   Session 9: Orally dosed biologicals (Auditorium)
Chair: Jaap Wieling, BiosanaPharma
  1. Oral delivery: Overcoming the hurdles of stability and poor intestinal permeability for macromolecules
    David Brayden, University College Dublin
  2. Oral administration of a GLP-1 analogue
    Stephen Buckley, NovoNordisk
  3. Exploring carrier peptides for oral delivery of therapeutic peptides
    Hanne Mørck Nielsen, University of Copenhagen
10.20 - 10.50   Tea/Coffee and Exhibition (CWB – Foyer & Plenary)
10.50 - 12.30   Session 10: Quantitative systems pharmacology and physiologically based pharmacokinetic modelling approaches (Auditorium)
Chair: Venkatesh Pilla Reddy, AstraZeneca
  1. Simulation of cellular drug responses within a whole-body context
    Lars Kuepfer, RWTH Aachen
  2. PBPK modelling to guide affinity optimisation of an antibody-drug conjugate in the presence of tumour target shedding
    Kathryn Ball, AstraZeneca
  3. Regulatory thoughts on PBPK and QSP models in patients
    Catriona Baker, MHRA
  4. Quantifying the right system correctly to obtain intrinsic drug data for scaling from in vitro to in vivo within PBPK modelling
    Sibylle Neuhoff, Certara
12.30 - 12.45   Dr Mira Doig – the life and times of a DMDG course organiser (Auditorium)
12.45 - 13.00   Closing Remarks – incoming DMDG Chair: Mark Seymour, Covance (Auditorium)
13.00 - 14.00   Lunch and delegates depart (CWB – Foyer & Plenary)

This meeting is sponsored by: